CDK1 and cancer: Therapeutic options for acquired PTX-resistant cancers have been developed, and these include targeting drug efflux17, CDK1 inhibitors14, stabilizing microtubules18, and epigenetic therapy to induce apoptosis and suppress angiogenesis19.